Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

By sjmartinez • November 2, 2023

McDermott MSJ, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol Cancer. 2023 Oct 30;22(1):175. doi: 10.1186/s12943-023-01890-z. Erratum for: Mol Cancer. 2014 Jun 24;13:157. PMID: 37915024.

Tags: Hematology/Oncology, Publications

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano[...]

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N,[...]

Novel Endocrine Therapies: Current Status and Future Directions

Brierley-Green E, Duggirala N, McCann KE, Callahan R, Bardia A, Lipsyc-Sharf M. Novel Endocrine Therapies: Current Status and Future Directions. Clin Breast Cancer. 2026 Aug[...]